Back to search results

Study on How Food Affects Prifetrastat Uptake

This study is looking for healthy adults to understand how food affects how much of the medicine Prifetrastat gets into your blood. Researchers want to see if eating a high-fat, high-calorie meal changes how your body absorbs Prifetrastat compared to taking it on an empty stomach. You would receive Prifetrastat as a single tablet on two separate occasions, once after eating and once on an empty stomach, with at least 14 days in between. The order of fed or fasted conditions will be decided randomly. The study aims to measure the total amount and peak level of Prifetrastat in your blood over several days after each dose. This study is currently unclear on its recruitment status and plans to enroll 12 participants.

Study design
This is an interventional study involving 12 healthy adult participants. Participants will receive Prifetrastat twice, once fed and once fasted, with the order randomized.
What's involved
You would take a single Prifetrastat tablet on two separate days, at least 14 days apart. Blood samples will be taken frequently over 144 hours (6 days) after each dose.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels of Prifetrastat will be measured for up to 144 hours (6 days) after each dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07731100

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

Not Yet Recruiting
PHASE1Ages 18+InterventionalBasic science
Pfizer
~12 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:Prifetrastat

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for Prifetrastat
Measured over 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose
+2 more outcomes measured

Conditions

Healthy Adults

Explore related trials

Healthy Volunteers

NCT07731100

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticutno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Females of nonchildbearing potential and males ≥18 years of age at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs.
Body mass Index (BMI) of 18-32 kg/m2; and a total body weight \>50 kg (110 lb).

Exclusion

Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention
Any prior use of epigenetic modifying agents.
Current use or anticipated need for food or drugs that are known moderate or strong inducers or inhibitors of CYP2C9 or CYP3A4, including their administration within 14 days plus 5 half-lives of the inducers or 14 days or 5 half lives (whichever is longer) for the inhibitors of CYP2C9 or CYP3A4, prior to first dose of study intervention, during the treatment period, and within 6 days after the last dose of prifetrastat.
Proton pump inhibitors must be discontinued at least 14 days prior to the first dose of study medication and throughout treatment period.

What this trial measures

  • Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for Prifetrastat0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose
  • Area under the concentration-time curve from time zero to time of last measurable concentration (AUClast) for Prifetrastat0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose
  • Maximum observed plasma concentration (Cmax) for Prifetrastat0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours post-dose